To investigate the molecular differences in alpha-synuclein (aSyn) pathology associated with clinical heterogeneity in Parkinson's disease (PD), emphasizing the significance of this understanding.
Key Findings:
Distinct molecular profiles of aSyn pathology were identified between EOPD and LOPD subgroups, suggesting different underlying mechanisms.
Differences in aSyn aggregation and seeding potential were observed in slow- and fast-progressing PD subgroups, with implications for treatment strategies.
Phosphorylation at serine-129 (pSer129) was significantly associated with aSyn aggregates in Lewy pathology, highlighting its potential as a biomarker.
Interpretation:
The study highlights the importance of molecular profiling in understanding the heterogeneity of PD, suggesting that different aSyn pathologies may underlie varied clinical presentations and disease trajectories, and indicating future research directions.
Limitations:
The cohort was limited to individuals of European descent, which may affect generalizability and introduce demographic biases.
Detailed clinical information was not available for all individuals due to the nature of post-mortem brain donations.
Conclusion:
Understanding the molecular basis of aSyn pathology could lead to more targeted therapeutic strategies for PD, addressing the diverse clinical manifestations of the disease and emphasizing the importance of personalized medicine.
by Zeynep Bengisu Kaya, Danilyn Amerna, Ananya Susarla, Melina J. Lim, Maria Bregendahl, Hiroaki Sekiya, Michael DeTure, Owen A. Ross, Dennis W. Dickson, Suelen L. Boschen, Pamela J. McLean
